Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Nature Cancer|June 21, 2022
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancerAya Shiba-Ishii, Ted W Johnson, Ibiayi Dagogo-Jack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung CancerJessica J Lin, Viola W Zhu, Satoshi Yoda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2020
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung CancerIbiayi Dagogo-Jack, Satoshi Yoda, Jochen K Lennerz, et al.
Cell|February 7, 2025
GUK1 activation is a metabolic liability in lung cancerJaime L Schneider, Kiran Kurmi, Yutong Dai, et al.
Cancer Discovery|December 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance MutationsAlexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Cancer Discovery|April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung CancerSatoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
Cancer Discovery|September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound MutationsJessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Cancer Discovery|September 28, 2018
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET FusionZofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2021
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung CancerJessica J Lin, Noura J Choudhury, Satoshi Yoda, et al.
JCO Precision Oncology|January 30, 2018
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNAIbiayi Dagogo-Jack, A Rose Brannon, Lorin A Ferris, et al.
Pageof 6